Executive at Pyxis Oncology (PYXS) receives new option and RSU equity grants

Rhea-AI Filing Summary

Pyxis Oncology, Inc. reported that principal financial and accounting officer Jitendra Wadhane received new equity compensation awards. He was granted a stock option for 262,635 shares of common stock at an exercise price of $1.36 per share, expiring on March 24, 2036. He also received 109,461 shares of common stock in the form of restricted stock units at no cost.

The restricted stock units vest 25% on March 31, 2026, then in 36 substantially equal monthly installments, subject to continued employment. The stock option vests 25% on the first anniversary of March 24, 2026, with the remainder vesting in 36 equal monthly installments on continued employment. Following these awards, his directly held common stock position is 512,882 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Wadhane Jitendra

Role Prin Fin & Acct Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	262,635	$0.00	--
Grant/Award	Common Stock	109,461	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 262,635 shares (Direct); Common Stock — 512,882 shares (Direct)

Footnotes (1)

1. Represents restricted stock units that vest 25% on March 31, 2026, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date. The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 24, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued emmployment through the applicable vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wadhane Jitendra

(Last) (First) (Middle)

C/O PYXIS ONCOLOGY, INC.

321 HARRISON AVENUE, 11TH FL. SUITE 1

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pyxis Oncology, Inc. [ PYXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Prin Fin & Acct Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		A		109,461(1)	A	$0	512,882	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.36	03/24/2026		A		262,635		(2)	03/24/2036	Common Stock	262,635	$0	262,635	D

Explanation of Responses:

1. Represents restricted stock units that vest 25% on March 31, 2026, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

2. The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 24, 2026 and the remainder vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued emmployment through the applicable vesting date.

	/s/ Jitendra Wadhane	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Pyxis Oncology (PYXS) report in this Form 4 for Jitendra Wadhane?

The filing shows Jitendra Wadhane received new equity compensation, including stock options and restricted stock units. These awards increase his potential ownership in Pyxis Oncology, aligning his interests with company performance over a multi-year vesting schedule.

How many stock options did Jitendra Wadhane receive from Pyxis Oncology (PYXS)?

He received a stock option covering 262,635 shares of Pyxis Oncology common stock. The option has an exercise price of $1.36 per share and expires on March 24, 2036, with vesting spread over four years based on continued employment.

What restricted stock unit (RSU) grant did Pyxis Oncology (PYXS) award to Jitendra Wadhane?

He was granted 109,461 shares of common stock in the form of restricted stock units at no purchase price. These RSUs vest 25% on March 31, 2026, then in 36 substantially equal monthly installments, contingent on his continued employment.

What are the vesting terms of Jitendra Wadhane’s new stock option at Pyxis Oncology (PYXS)?

The option vests 25% on the first anniversary of March 24, 2026. The remaining 75% vests in 36 equal monthly installments thereafter, provided he remains employed through each applicable vesting date under the award’s terms.

How many Pyxis Oncology (PYXS) common shares does Jitendra Wadhane hold after these grants?

After the reported equity awards, he directly holds 512,882 shares of Pyxis Oncology common stock. This figure reflects his updated ownership position following the grant of 109,461 restricted stock units reported in the Form 4.

Were these Pyxis Oncology (PYXS) transactions open-market purchases or compensation grants?

These transactions are compensation-related grants, not open-market trades. Both the stock option for 262,635 shares and the 109,461 restricted stock units were awarded at no purchase price as part of his executive compensation package.